Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Resuqing is a traditional Chinese medicine (TCM) formulation specifically developed for pediatric use to treat the common cold and influenza. It is composed of eight primary ingredients: *Bupleurum chinense* (Chaihu), *Scutellaria baicalensis* (Huangqin), *Isatis indigotica* (Banlangen), *Pueraria lobata* (Gegen), *Lonicera japonica* (Jinyinhua), *Bubalus bubalis* (water buffalo horn), *Forsythia suspensa* (Lianqiao), and *Rheum palmatum* (Dahuang). The formulation is designed to clear heat, detoxify, and relieve the exterior, making it effective for symptoms such as high fever, sore throat, cough, headache, and constipation. It is a well-established product in China, listed in the National Essential Medicines Catalogue and the National Medical Insurance Directory, and is available in oral liquid, granule, and syrup forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Resuqing.